Precigen

Precigen News

Precigen Q3 2026: $72.9M Revenue, Back-to-Back Profitability Mark Commercial Turning Point

Precigen posted $72.9 million in Q3 2026 net product revenue and achieved back-to-back quarterly profitability as commercial adoption of its UltraCAR-T point-of-care cell therapy technology accelerated, marking a turning point from development-stage losses to self-funding commercial operat

Nov 6, 2026

🇺🇸 United States

Precigen Director Jeffrey Kindler Disposes of 185,000 PGEN Shares in August 2026 Filing

Precigen (PGEN) director Jeffrey Kindler sold 185,000 shares on August 26, 2026 per SEC Form 4

Aug 30, 2026